Clinical and Prognostic Value of Sarcopenia in Patients Older Than 70 Years With Diffuse Large B-cell Lymphoma
NCT01715961 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 98
Last updated 2016-10-05
Summary
This clinical trial is a multicentric prospective study to assess the clinical and prognostic value of sarcopenia in patients older than 70 years with diffuse large B-cell lymphoma.
Conditions
- Diffuse Large B Cell Lymphoma
- Grade IIIB Follicular Lymphoma
Interventions
- PROCEDURE
-
anthropometric measurement
To attest the muscular strength: hand grip test, balance test, up and go test
Sponsors & Collaborators
-
Centre Henri Becquerel
lead OTHER
Principal Investigators
-
Fabrice JARDIN, MD;PhD · Centre Henri Becquerel
Study Design
- Allocation
- NA
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-01-31
- Primary Completion
- 2015-12-31
- Completion
- 2016-08-31
Countries
- France
Study Locations
More Related Trials
-
Prospective Analysis of Circulating Nucleosomes in Patients Receiving a First Line Treatment for a Non-Hodgkin Lymphoma
NCT06813573 ·Status: RECRUITING ·Phase: NA
-
Radiomics and Metabolomics in the Follow-up of CAR T-cells for Refractory or Relapsed Non-Hodgkin's Lymphoma
NCT05422521 ·Status: RECRUITING ·Phase: NA
-
Evaluate a Treatment Adapted to the PET Response Compared to a Standard Treatment, for Low Risk DLBCL CD 20+ Patients
NCT01285765 ·Status: COMPLETED ·Phase: PHASE3
-
AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL
NCT07215585 ·Status: RECRUITING ·Phase: PHASE3
-
GA In NEwly Diagnosed Diffuse Large B Cell Lymphoma
NCT01659099 ·Status: TERMINATED ·Phase: PHASE3
-
Retrospective Analysis of Rituximab-containing Immunochemotherapy for Burkitt's or Burkitt-like Lymphoma in Adults
NCT01809600 ·Status: COMPLETED
-
Efficacy of Lenalidomide in Combination With Subcutaneous Rituximab + miniCHOP in DLBCL Patients of 80 y/o or+
NCT02128061 ·Status: COMPLETED ·Phase: PHASE3
-
Lean Body Mass and Side Effects in Patients With Lymphoma
NCT04698616 ·Status: UNKNOWN
-
GA101-miniCHOP Regimen for the Treatment of Elderly Unfit Patients With Diffuse Large B-cell Non-Hodgkin's Lymphoma
NCT02495454 ·Status: TERMINATED ·Phase: PHASE2
-
ACVBP Plus Rituximab in Patients Aged From 18 to 59 Years With High-risk Diffuse Large B-cell Lymphoma
NCT00144807 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older
NCT04974216 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Multicenter Prospective Registry Study of Diffuse Large B Cell Lymphoma
NCT02474550 ·Status: UNKNOWN
-
Phase II Prospective Trial of Addition of Rituximab to Reduced Dose CHOP Chemotherapy in DLBC L Patients Aged 65 Years and Over
NCT02792491 ·Status: UNKNOWN ·Phase: PHASE2
-
ACVBP Followed by ASCT in Patients With BCL-2 Positive Diffuse Large B-Cell Lymphoma
NCT00169130 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Lymphoma Follow-up
NCT00744120 ·Status: COMPLETED
-
Impact of Lymphodepletion Regimen on the Response to CAR T-cells in Patients With With Relapsed/Refractory Large B-cell Lymphoma
NCT06988085 ·Status: NOT_YET_RECRUITING
-
Rituximab Plus Bendamustine as Front Line Treatment in Frail Elderly (>70 Years) Patients With DLBCL: a Phase II Multicenter Study of the FIL
NCT01990144 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of Oral LY317615 in Relapsed or Refractory Diffuse Large B-Cell Lymphomas.
NCT00042666 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma
NCT00690560 ·Status: COMPLETED ·Phase: PHASE2
-
R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-cell Lymphoma
NCT00135499 ·Status: TERMINATED ·Phase: PHASE3
-
Study of Mini-Chop Plus Ofatumumab To Treat Cd 20+ Diffuse Large B-Cell Lymphoma In Patients Aged Over 80 Years
NCT01195714 ·Status: COMPLETED ·Phase: PHASE2
-
Prospective Cohort Study With Central Nervous System Evaluation in Diffuse Large B-cell Lymphoma
NCT01202448 ·Status: COMPLETED ·Phase: NA
-
ACVBP Versus ACVBP Plus Rituximab in Low Risk Localized Diffuse Large B-cell Lymphoma
NCT00140660 ·Status: TERMINATED ·Phase: PHASE3
-
Elderly Hodgkin Lymphoma Patients Treated With Chemoradiotherapy
NCT03535948 ·Status: UNKNOWN
-
Assessment of Survival and Autonomy With Rituximab Plus Chemotherapy or Rituximab Plus Lenalidomide for Elderly Patients With Relapsed Diffuse Large B-cell Lymphoma
NCT04113226 ·Status: UNKNOWN ·Phase: PHASE2